glp-1 medications and alcohol medications: The next big thing in use disorder treatment? – Recovery Research Institute Understanding GLP-1 Agonists and Alcohol

Anita Skrtic, [email protected] This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

IN THIS ECONOMY?? That's a wrap on this edition

That framing is helpful because it shows the identity of the stack isnt tied to one peptide alone

One of topiramates unique strengths is its ability to help patients slow down their eating pace

Neither BPC-157 nor TB-500 is FDA-approved, and the FDA has specifically flagged BPC-157, so these remain research-stage compounds discussed only in a wellness-support context